{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T21:03:25Z","timestamp":1780002205429,"version":"3.53.1"},"reference-count":54,"publisher":"Elsevier","isbn-type":[{"value":"9780443417610","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.ircmb.2025.03.003","type":"book-chapter","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T22:44:34Z","timestamp":1743893074000},"page":"113-138","source":"Crossref","is-referenced-by-count":0,"title":["Immunocytokines based on IL-12 for cancer therapy: Enhancing efficacy and reducing toxicity"],"prefix":"10.1016","author":[{"given":"Uxue","family":"Beloki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Salaberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Covo-Vergara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Ortu\u00f1o-Moya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Silva-Pilipich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Smerdou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/bs.ircmb.2025.03.003_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2019.08.006","article-title":"An overview of monoclonal antibodies","volume":"35","author":"Bayer","year":"2019","journal-title":"Seminars in Oncology Nursing"},{"issue":"16","key":"10.1016\/bs.ircmb.2025.03.003_bib2","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1158\/1078-0432.CCR-07-0776","article-title":"Interleukin-12: Biological properties and clinical application","volume":"13","author":"Del Vecchio","year":"2007","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2025.03.003_bib3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.omtn.2023.07.020","article-title":"Intratumoral injection of IL-12-encoding mRNA targeted to CSFR1 and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure","volume":"33","author":"Di Trani","year":"2023","journal-title":"Molecular Therapy. Nucleic Acids"},{"issue":"6","key":"10.1016\/bs.ircmb.2025.03.003_bib4","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1323161","article-title":"Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo","volume":"6","author":"Eckert","year":"2017","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1016\/bs.ircmb.2025.03.003_bib5","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00262-016-1863-0","article-title":"Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models","volume":"65","author":"Eckert","year":"2016","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"issue":"7","key":"10.1016\/bs.ircmb.2025.03.003_bib6","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.18632\/oncotarget.1853","article-title":"The immunocytokine NHS-IL12 as a potential cancer therapeutic","volume":"5","author":"Fallon","year":"2014","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/bs.ircmb.2025.03.003_bib7","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: A new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Science"},{"issue":"9","key":"10.1016\/bs.ircmb.2025.03.003_bib8","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/ijc.22101","article-title":"An engineered antibody\u2013interleukin\u201012 fusion protein with enhanced tumor vascular targeting properties","volume":"119","author":"Gafner","year":"2006","journal-title":"International Journal of Cancer"},{"issue":"4","key":"10.1016\/bs.ircmb.2025.03.003_bib9","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/oncolo\/oyac244","article-title":"A phase I single-arm study of biweekly NHS-IL12 in patients with metastatic solid tumors","volume":"28","author":"Gatti-Mays","year":"2023","journal-title":"The Oncologist"},{"issue":"12","key":"10.1016\/bs.ircmb.2025.03.003_bib10","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.4049\/jimmunol.160.12.6195","article-title":"Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases","volume":"160","author":"Gillies","year":"1998","journal-title":"The Journal of Immunology"},{"key":"10.1016\/bs.ircmb.2025.03.003_bib11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/ITT.S306150","article-title":"NHS-IL12, a tumor-targeting immunocytokine","volume":"10","author":"Greiner","year":"2021","journal-title":"ImmunoTargets and Therapy"},{"issue":"12","key":"10.1016\/bs.ircmb.2025.03.003_bib12","first-page":"3202","article-title":"Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to Tumor Necrosis Factor \u03b1","volume":"63","author":"Halin","year":"2003","journal-title":"Cancer Research"},{"issue":"9","key":"10.1016\/bs.ircmb.2025.03.003_bib13","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00262-007-0297-0","article-title":"Long-term immunity elicited by antibody-cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies","volume":"56","author":"Helguera","year":"2007","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"4","key":"10.1016\/bs.ircmb.2025.03.003_bib14","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ijc.11279","article-title":"Anti-CD30-IL-12 antibody-cytokine fusion protein that induces IFN-\u03b3 secretion of T cells and NK cell-mediated lysis of Hodgkin\u2019s lymphoma-derived tumor cells","volume":"106","author":"Heuser","year":"2003","journal-title":"International Journal of Cancer"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.03.003_bib15","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1038\/s41467-021-25393-x","article-title":"Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape","volume":"12","author":"Hicks","year":"2021","journal-title":"Nature Communications"},{"key":"10.1016\/bs.ircmb.2025.03.003_bib16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.addr.2018.09.002","article-title":"Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy","volume":"141","author":"Hutmacher","year":"2019","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/bs.ircmb.2025.03.003_bib17","doi-asserted-by":"crossref","first-page":"1034774","DOI":"10.3389\/fimmu.2022.1034774","article-title":"Improved intratumoral penetration of IL12 immunocytokine enhances the antitumor efficacy","volume":"13","author":"Jung","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"11","key":"10.1016\/bs.ircmb.2025.03.003_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0081919","article-title":"Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/bs.ircmb.2025.03.003_bib19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00262-014-1523-1","article-title":"Interleukin 12: Still a promising candidate for tumor immunotherapy?","volume":"63","author":"Lasek","year":"2014","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"issue":"6","key":"10.1016\/bs.ircmb.2025.03.003_bib20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic viruses in cancer treatment: A review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncology"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.03.003_bib21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nbt0197-35","article-title":"Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo","volume":"15","author":"Lieschke","year":"1997","journal-title":"Nature Biotechnology"},{"issue":"4","key":"10.1016\/bs.ircmb.2025.03.003_bib22","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00262-006-0203-1","article-title":"huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models","volume":"56","author":"Lo","year":"2007","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"issue":"7","key":"10.1016\/bs.ircmb.2025.03.003_bib23","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/s41551-022-00888-0","article-title":"Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker","volume":"6","author":"Mansurov","year":"2022","journal-title":"Nature Biomedical Engineering"},{"issue":"6","key":"10.1016\/bs.ircmb.2025.03.003_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004561","article-title":"Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1\/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies","volume":"10","author":"Minnar","year":"2022","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/bs.ircmb.2025.03.003_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2023.102994","article-title":"Balancing safety and efficacy: Tuning the biodistribution and pharmacokinetics of cytokine immunotherapies","volume":"84","author":"Momin","year":"2023","journal-title":"Current Opinion in Biotechnology"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.03.003_bib26","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s40425-019-0620-2","article-title":"Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12","volume":"7","author":"Morillon","year":"2019","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/bs.ircmb.2025.03.003_bib27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.nbt.2019.04.002","article-title":"Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation","volume":"52","author":"Murer","year":"2019","journal-title":"New Biotechnology"},{"issue":"9","key":"10.1016\/bs.ircmb.2025.03.003_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005282","article-title":"Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody","volume":"10","author":"Nadal","year":"2022","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/bs.ircmb.2025.03.003_bib29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.coi.2016.03.006","article-title":"Immunocytokines for cancer treatment: Past, present and future","volume":"40","author":"Neri","year":"2016","journal-title":"Current Opinion in Immunology"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.03.003_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsb.2021.107696","article-title":"Inference of molecular structure for characterization and improvement of clinical grade immunocytokines","volume":"213","author":"Ongaro","year":"2021","journal-title":"Journal of Structural Biology"},{"key":"10.1016\/bs.ircmb.2025.03.003_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jbiotec.2018.12.004","article-title":"A novel anti-cancer L19-interleukin-12 fusion protein with an optimized peptide linker efficiently localizes in vivo at the site of tumors","volume":"291","author":"Ongaro","year":"2019","journal-title":"Journal of Biotechnology"},{"issue":"6","key":"10.1016\/bs.ircmb.2025.03.003_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129954","article-title":"Defining the pharmacodynamic profile and therapeutic index of NHS-IL12 immunocytokine in dogs with malignant melanoma","volume":"10","author":"Paoloni","year":"2015","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/bs.ircmb.2025.03.003_bib33","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1158\/1078-0432.CCR-12-0282","article-title":"The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel","volume":"18","author":"Pasche","year":"2012","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.03.003_bib34","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4049\/jimmunol.163.1.250","article-title":"A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity","volume":"163","author":"Peng","year":"1999","journal-title":"The Journal of Immunology"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.03.003_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19420862.2023.2217964","article-title":"Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen","volume":"15","author":"Pl\u00fcss","year":"2023","journal-title":"MAbs"},{"issue":"5","key":"10.1016\/bs.ircmb.2025.03.003_bib36","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1158\/2326-6066.CIR-14-0216","article-title":"Virotherapy with a semliki forest virus-based vector encoding IL12 synergizes with PD-1\/PD-L1 blockade","volume":"3","author":"Quetglas","year":"2015","journal-title":"Cancer Immunology Research"},{"issue":"7","key":"10.1016\/bs.ircmb.2025.03.003_bib37","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1158\/1078-0432.CCR-10-2490","article-title":"A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma","volume":"17","author":"Rudman","year":"2011","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"10.1016\/bs.ircmb.2025.03.003_bib38","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1014760","article-title":"Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation","volume":"4","author":"Schilbach","year":"2015","journal-title":"Oncoimmunology"},{"issue":"5\u20136","key":"10.1016\/bs.ircmb.2025.03.003_bib39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/15368590152740707","article-title":"Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors","volume":"20","author":"Sharifi","year":"2001","journal-title":"Hybridoma and Hybridomics"},{"issue":"5","key":"10.1016\/bs.ircmb.2025.03.003_bib40","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Current Oncology (Toronto, Ont.)"},{"key":"10.1016\/bs.ircmb.2025.03.003_bib41","article-title":"Targeting PD-1+ T cells with small-format immunocytokines enhances IL-12 antitumor activity","author":"Silva-Pilipich","year":"2024","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2025.03.003_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216139","article-title":"Local delivery of optimized nanobodies targeting the PD-1\/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses","volume":"561","author":"Silva-Pilipich","year":"2023","journal-title":"Cancer Letters"},{"key":"10.1016\/bs.ircmb.2025.03.003_bib43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/bs.ircmb.2023.05.006","article-title":"Checkpoint blockade meets gene therapy: Opportunities to improve response and reduce toxicity","volume":"379","author":"Silva-Pilipich","year":"2023","journal-title":"International Review of Cell and Molecular Biology"},{"issue":"12","key":"10.1016\/bs.ircmb.2025.03.003_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8120562","article-title":"Long-term systemic expression of a novel PD-1 blocking nanobody from an AAV vector provides antitumor activity without toxicity","volume":"8","author":"Silva-Pilipich","year":"2020","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.03.003_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000612","article-title":"Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine","volume":"8","author":"Smalley Rumfield","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"8","key":"10.1016\/bs.ircmb.2025.03.003_bib46","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/protein\/gzq038","article-title":"Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12","volume":"23","author":"Sommavilla","year":"2010","journal-title":"Protein Engineering, Design & Selection: PEDS"},{"issue":"5","key":"10.1016\/bs.ircmb.2025.03.003_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005813","article-title":"First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma","volume":"11","author":"Strauss","year":"2023","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.03.003_bib48","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1158\/1078-0432.CCR-18-1512","article-title":"First-in-human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors","volume":"25","author":"Strauss","year":"2019","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"4","key":"10.1016\/bs.ircmb.2025.03.003_bib49","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","article-title":"The immunobiology of the interleukin-12 family: Room for discovery","volume":"50","author":"Tait Wojno","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/bs.ircmb.2025.03.003_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109736","article-title":"Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12","volume":"116","author":"Toney","year":"2023","journal-title":"International Immunopharmacology"},{"issue":"2","key":"10.1016\/bs.ircmb.2025.03.003_bib51","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/cdd.2014.134","article-title":"New insights into IL-12-mediated tumor suppression","volume":"22","author":"Tugues","year":"2015","journal-title":"Cell Death and Differentiation"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.03.003_bib52","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01677-19","article-title":"Engineering newcastle disease virus as an oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines","volume":"94","author":"Vijayakumar","year":"2020","journal-title":"Journal of Virology"},{"issue":"19","key":"10.1016\/bs.ircmb.2025.03.003_bib53","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-17-0483","article-title":"Combination therapy with NHS-muIL12 and avelumab (anti-PD-L1) enhances antitumor efficacy in preclinical cancer models","volume":"23","author":"Xu","year":"2017","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.03.003_bib54","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1038\/s41467-024-49034-1","article-title":"Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8+T cells for systemic antitumor responses","volume":"15","author":"Zou","year":"2024","journal-title":"Nature Communications"}],"container-title":["International Review of Cell and Molecular Biology","Cytokine-based immunotherapy - Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644825000383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644825000383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T20:18:55Z","timestamp":1779999535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644825000383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443417610"],"references-count":54,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2025.03.003","relation":{},"ISSN":["1937-6448"],"issn-type":[{"value":"1937-6448","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}